Interactions between leukotrienes and other inflammatory mediators/modulators in the microvasculature

American Journal of Respiratory and Critical Care Medicine

Volumn 161, Issue 2 II, 2000, Pages

  Hedqvist, Per ^a   Gautam, Narinder ^a   Lindbom, Lennart ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE; IMMUNOMODULATING AGENT; LEUKOTRIENE; LIPOXIN; PROSTAGLANDIN;

BLOOD VESSEL PERMEABILITY; HOST RESISTANCE; IMMUNOREGULATION; INFLAMMATION; MAST CELL; MEDIATOR RELEASE; MICROVASCULATURE; PRIORITY JOURNAL; REVIEW;

EID: 0034056742     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.161.supplement_1.ltta-23     Document Type: Review

References (43)

1. Malmsten, C. L. 1984. Leukotrienes: mediators of inflammation and immediate hypersensitivity reactions. Crit. Rev. Immunol. 4:307-334.
2. Lewis, R. A., K. F. Austen, and R. J. Soberman. 1990. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N. Engl. J. Med. 323:645-655.
3. Keppler, D., A. Guhlmann, F. Oberdorfer, K. Krauss, J. Muller, H. Ostertag, and M. Huber. 1991. Generation and metabolism of cysteinyl leukotrienes in vivo. Ann. N.Y. Acad. Sci. 629:100-104.
4. Dahlén, S.-E., J. Björk, P. Hedqvist, K. E. Arfors, S. Hammarström, J. A. Lindgren, and B. Samuelsson. 1981. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc. Natl. Acad. Sci U.S.A. 78:3887-3891.
5. 4) in human skin. J. Invest. Dermatol. 80:115-119.
6. 4. Acta Physiol. Scand. 110:331-333.
7. 4: endothelial contraction. Am. J. Pathol. 126:19-24.
8. Smith, M. J., A. W. Ford-Hutchinson, and M. A. Bray. 1980. Leukotriene B: a potential mediator of inflammation. J. Pharm. Pharmacol. 32:517-518.
9. 4 is a potent and stereospecific stimulator of neutrophil chemotaxis and adherence. Blood 58:658-661.
10. 4: its effects on cation homeostasis in rabbit neutrophils. J. Cell. Physiol. 108:401-408.
11. 4 produces hyperalgesia that is dependent on polymorphonuclear leukocytes. Science 225:743-745.
12. 4 induces extravasation and migration of polymorphonuclear leukocytes in vivo. Acta Physiol. Scand. 116:105-108.
13. 4 and the role of polymorphonuclear leukocytes. Inflammation 6:189-200.
14. 4: lack of structural injury to the endothelium. Tissue Cell 18:1-12.
15. Arfors, K. E., C. Lundberg, L. Lindbom, K. Lundberg, P. G. Beatty, and J. M. Harlan. 1987. A monoclonal antibody to the membrane glycoprotein complex CD18 inhibits polymorphonuclear leukocyte accumulation and plasma leakage in vivo. Blood 69:338-340.
16. Gautam, N., P. Hedqvist, and L. Lindbom. 1998. Kinetics of leukocyte-induced changes in endothelial barrier function. Br. J. Pharmacol. 125:1109-1115.
17. Raud, J. 1989. Intravital microscopic studies on acute mast cell-dependent inflammation. Acta Physiol. Scand. 135(Suppl. 578):1-58.
18. 2: apparent correlation with in vivo modulation of mediator release. Proc. Natl Acad. Sci. U.S.A. 85:2315-2319.
19. Hedqvist, P., J. Raud, and S.-E. Dahlén. 1990. Microvascular actions of eicosanoids in the hamster cheek pouch. Adv. Prostaglandin Thromboxane Leukotriene Res. 20:153-160.
20. Hedqvist, P., J. Raud, U. Palmertz, M. Kumlin, and S.-E. Dahlén. 1991. Eicosanoids as mediators and modulators of inflammation. Adv. Prostaglandin Thromboxane Leukotriene Res. 21B:537-543.
21. Hedqvist, P., L. Lindbom, U. Palmertz, and J. Raud. 1994. Microvascular mechanisms in inflammation. Adv. Prostaglandia Thromboxane Leukotriene Res. 22:91-99.
22. Serhan, C. N. 1994. Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochem. Biophys. Acta 1212:1-23.
23. Serhan, C. N. 1997. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity? Prostaglandins 53:107-137.
24. 4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. J. Immunol. 156:2264-2272.
25. Vane, J. R. 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (London) 231:232-235.
26. Williams, T. J. 1977. Chemical mediators of vascular responses in inflammation: a two mediator hypothesis. Br. J. Pharmacol. 61:447P-448P.
27. 4: a mediator of vascular permeability. Br. J. Pharmacol. 72:483-486.
28. Williams, T. J. 1983. Interactions between prostaglandins, leukotrienes and other mediators of inflammation. Br. Med. Bull. 9:239-242.
29. Raud, J. 1990. Vasodilalion and inhibition of mediator release represent two distinct mechanisms for prostaglandin modulation of acute mast cell-dependent inflammation. Br. J. Pharmacol. 99:449-454.
30. 4 release from activated neutrophils. Proc. Natl. Acad. Sci. U.S.A. 80:4349-4353.
31. Bonta, I. L., and M. J. Parnham. 1982. Immunomodulatory-antiinflammatory functions of E-type prostaglandins: minireview with emphasis on macrophage-mediated effects. Int. J. Immunopharmacol. 4:103-109.
32. Levi, R., G. Allan, and H. Zavecz. 1976. Prostaglandins and cardiac anaphylaxis. Life Sci. 18:1255-1264.
33. 2α on the immunologic release of mediators of inflammation from actively sensitized guinea-pig lung. J. Pharmacol. Exp. Ther. 207:630-640.
34. Raud, J. 1990. Vasodilatation and inhibition of mediator release represent two distinct mechanisms for prostaglandin modulation of acute mast cell-dependent inflammation. Br. J. Pharmacol. 99:449-454.
35. 4 act synergistically via a blood flow-independent mechanism to enhance microvascular plasma leakage. Acta Physiol Scand. 146:545-546.
36. Raud, J., H. Thorlacius, X. Xie, L. Lindbom, and P. Hedqvist. 1994. Interactions between histamine and leukotrienes in the microcirculation: aspects of relevance to acute allergic inflammation. Ann. N.Y. Acad. Sci. 744:191-198.
37. 2-receptor involvement in cosinophil infiltration and the microvascular changes associated with cutaneous anaphylaxis. Agents Actions 17:121-125.
38. Ciprandi, G., S. Buscaglia, A. Iudice, and G. W. Canonica. 1992. Protective effect of different doses of terfenadine on the conjunctival provocation test. Allergy 47:309-312.
39. Hedqvist, P., L. Lindbom, H. Thorlacius, and J. Raud. 1996. Microvascular actions and interactions of eicosanoids and histamine in inflammation. In G.-C. Folco, editor. Eicosanoids: From Biotechnology to Therapeutic Applications. Plenum Press, New York. [NATO ASI, Series A; Life Sci. 283:155-163].
40. Lindbom, L., X. Xie, J. Raud, and P. Hedqvist. 1992. Chemoattractant-induced leukocyte adhesion to vascular endothelium in vivo is critically dependent on initial leukocyte rolling. Acta Physiol. Scand. 146:415-421.
41. Thorlacius, H., J. Raud, X. Xie, P. Hedqvist, and L. Lindbom. 1995. Microvascular mechanisms of histamine-induced potentiation of leukocyte adhesion evoked by chemoattractants. Br. J. Pharmacol. 116:3175-3180.
42. Majno, G., and G. E. Palade. 1961. Studies on inflammation: I. The effect of histamine and serotonin on vascular permeability: an electron microscopic study. J. Biophys. Biochem. Cytol. 11:571-605.
43. Thorlacius, H., and X. Xie. 1995. Histamine modulates the nature of fMLP-induced leukocyte adhesion. Acta Physiol. Scand. 155:475-476.